NRC HEALTH — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
NRC Health reported Q3 2026 revenue of $38.4M (up 11% YoY) and TRCV of $154.1M (up 9% YoY). Net income was $4.7M ($0.21 diluted EPS) on 21.9M diluted shares. The Board declared a quarterly dividend of $0.16/share, payable January 8, 2027 to shareholders of record December 29, 2026. Nine-month 2026 results show revenue of $108.6M (+6.3% YoY) but net income of $4.6M, down 53% from $9.8M in nine-month 2025, reflecting management transition costs of $3.2M YTD.
Why this rating
Revenue growth modest at 11%; profitability declined YTD despite Q3 strength. Debt increased materially (notes payable $102.9M vs $79M end-2025). Negative equity ($9.1M) concerning. Dividend sustainable but no transformational change.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.